Vice President, Oncology and Angiogenesis Research, Regeneron Pharmaceuticals
Gavin Thurston, PhD, has been with Regeneron for almost 20 years. Initially, studying the interaction of the VEGF signaling pathway with other angiogenic pathways and trying to target these pathways for the treatment of cancer. In more recent years, he has led Regeneron’s efforts to develop therapeutic antibodies to modulate the immune system for immuno-oncology and to target tumor cells with bispecific antibodies and antibody drug conjugates. He received his undergraduate degree in Physics from Yale University and his PhD in Biophysics from University of British Columbia.